Management of Sexual Dysfunction in Postmenopausal Breast Cancer Patients Taking Adjuvant Aromatase Inhibitor Therapy

The 2007 document discussed the management of sexual dysfunction in postmenopausal breast cancer patients undergoing adjuvant aromatase inhibitor therapy. The therapy often led to sexual dysfunction due to diminished estrogen synthesis, causing symptoms like hot flushes, vaginal dryness, painful intercourse, and loss of sexual interest. Non-hormonal alternatives were recommended as first-line therapy for urogenital symptoms, with hormonal interventions considered if these failed. The document also discussed the potential benefits and risks of hormone therapy, including testosterone therapy, which required close monitoring for skin and hair problems, including androgenic alopecia. The document emphasized the importance of a biopsychosocial approach to assessment and management, including education, lifestyle changes, sexual counselling, pelvic floor therapies, sexual aids, medications, and dietary supplements.